CorMedix Inc (CRMD NASDAQ) stock market data APIs
$6.5401
-0.27(-4.1%)
as of March 9, 2026
Try our APIs with
free plan!
CorMedix Inc Financial Data Overview
Price chart is built with
Anychart
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
Prev. Close
6.5401
Open
6.2727
High
6.5563
Low
6.0959
52 wk Range
5.6-17.43
Market Cap
509 M
P/E Ratio
2.9231
Shares Outstanding
78 789 K
Revenue
312 M
EPS
1.406
Beta
1.421
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with CorMedix Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CorMedix Inc data using free add-ons & libraries
Get CorMedix Inc Fundamental Data
CorMedix Inc Fundamental data includes:
- Net Revenue: 312 M
- EBITDA: 175 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-28
- EPS/Forecast: 0.2233
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CorMedix Inc News
New
CorMedix Q4 Revenue Improves; Reaffirms FY26 Outlook; Plans To Report Phase III REZZAYO Data In Q2
(RTTNews) - CorMedix Inc. (CRMD), a biopharmaceutical company, announced financial results for the fourth quarter and full-year 2025 with revenue growth. In addition, the firm reaffirmed full-year 202...
CorMedix outlines $300M–$320M revenue and $100M–$125M EBITDA targets for 2026 amid DefenCath transition and Melinta integration
Earnings Call Insights: CorMedix Inc. (CRMD) Q4 2025 MANAGEMENT VIEW * CEO Joseph Todisco stated that “2025 was truly a transformational year for CorMedix. While DefenCath achieved peak sales of...
CorMedix Inc. Q4 Sales Increase
(RTTNews) - CorMedix Inc. (CRMD) released a profit for fourth quarter of $14.02 million The company's earnings totaled $14.02 million, or $0.16 per share. This compares with $13.47 million, or $0.20...
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Confer...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
